补中益气汤联合贝伐珠单抗对晚期肺腺癌化疗患者中医证候及肿瘤标志物水平的影响

Effects of Buzhong Yiqi decoction combined with bevacizumab on traditional Chinese medicine syndromes and tumor marker levels in patients with advanced lung adenocarcinoma undergoing chemotherapy

目的探究补中益气汤联合贝伐珠单抗对晚期肺腺癌化疗患者中医证候及肿瘤标志物水平的影响。方法选取2019年3月—2022年4月聊城市茌平区人民医院收治的68例晚期肺腺癌化疗患者作为研究对象,按照随机数字表法分为两组,每组34例。对照组患者采用常规化疗方案+贝伐珠单抗治疗,研究组在上述治疗基础上联合补中益气汤。两组连续服用9周。比较两组临床疗效、中医证候积分、肿瘤标志物[癌胚抗原(carcinoembryonic antigen,CEA)、糖类抗原125(carbohydrate antigen 125,CA125)、细胞角质蛋白19片段抗原21-1(cytokeratin 19 fragment antigen 21-1,CYFRA21-1)]水平及不良反应情况。结果研究组疾病缓解率为32.35%、疾病控制率为85.29%,均高于对照组的11.76%、58.85%,差异有统计学意义(P<0.05)。治疗后,研究组主证与次证积分、各肿瘤标志物水平均低于对照组,差异有统计学意义(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论补中益气汤联合贝伐珠单抗在晚期肺腺癌化疗患者应用中可有效控制病情进展,降低各肿瘤标志物水平,缓解临床症状。

Objective To determine the effect of Buzhong Yiqi decoction combined with bevacizumab on traditional Chinese medicine(TCM)syndromes and tumor marker levels in patients with advanced lung adenocarcinoma undergoing chemotherapy.Methods Sixty-eight patients with advanced lung adenocarcinoma undergoing chemotherapy in People’s Hospital of Chiping District from March 2019 to April 2022 were enrolled in the current study.The patients were divided into two groups based on the random number table method,with 34 patients in each group.The patients in the control group were treated with a conventional chemotherapy regimen+bevacizumab.The patients in the study group were treated with bevacizumab+Buzhong Yiqi decoction.The two groups were treated for 9 consecutive weeks.The clinical efficacy,TCM syndromes scores,tumor marker[carcinoembryonic antigen(CEA),carbohydrate antigen 125(CA125),and cytokeratin 19 fragment antigen 21-1(CYFRA21-1)]levels,and adverse reactions were compared between the two groups.Results The disease remission and disease control rates were 32.35%and 85.29%,respectively,in the study group,which were higher than in the control group(11.76%and 58.85%,respectively;P<0.05).After treatment,the scores of the main and secondary syndromes and the levels of each tumor marker in the study group were lower than those in the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Buzhong Yiqi decoction combined with bevacizumab effectively controlled disease progression,reduced the levels of various tumor markers,and relieved various clinical symptoms in patients with advanced lung adenocarcinoma chemotherapy,which is worthy of consideration as a treatment option.